Gormley G - Search Results

1

Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group.

Oesterling JE, Roy J, Agha A, Shown T, Krarup T, Johansen T, Lagerkvist M, Gormley G, Bach M, Waldstreicher J. Oesterling JE, et al. Among authors: gormley g. Urology. 1997 Jul;50(1):13-8. doi: 10.1016/s0090-4295(97)00156-8. Urology. 1997. PMID: 9218012 Clinical Trial.

2

Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. Finasteride PSA Study Group.

Oesterling JE, Roy J, Agha A, Shown T, Krarup T, Johansen T, Lagerkvist M, Gormley G, Bach M, Waldstreicher J. Oesterling JE, et al. Among authors: gormley g. Urology. 1998 Apr;51(4A Suppl):58-63. doi: 10.1016/s0090-4295(98)00059-4. Urology. 1998. PMID: 9586598

3

The effect of finasteride on prostate specific antigen: review of available data.

Guess HA, Gormley GJ, Stoner E, Oesterling JE. Guess HA, et al. Among authors: gormley gj. J Urol. 1996 Jan;155(1):3-9. J Urol. 1996. PMID: 7490873 Review.

4

Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American phase III clinical trial.

Guess HA, Heyse JF, Gormley GJ, Stoner E, Oesterling JE. Guess HA, et al. Among authors: gormley gj. Urol Clin North Am. 1993 Nov;20(4):627-36. Urol Clin North Am. 1993. PMID: 7505970 Clinical Trial.

5

Improvement of pressure flow parameters with finasteride is greater in men with large prostates. Finasteride Urodynamics Study Group.

Abrams P, Schäfer W, Tammela TL, Barrett DM, Hedlund H, Rollema HJ, Matos-Ferreira A, Nordling J, Bruskewitz R, Andersen JT, Hald T, Miller P, Kirby R, Mustonen S, Cannon A, Jacobsen CA, Gormley GJ, Malice MP, Bach MA. Abrams P, et al. Among authors: gormley gj. J Urol. 1999 May;161(5):1513-7. J Urol. 1999. PMID: 10210385 Clinical Trial.

6

Endocrine therapies for BPH: scientific rationale, clinical results, and patient selection.

Oesterling JE, el Etreby MF, Gormley GJ, Imperato-McGinley JL, Roehrborn CG, Schröder FH, Tunn UW. Oesterling JE, et al. Among authors: gormley gj. Prog Clin Biol Res. 1994;386:231-50. Prog Clin Biol Res. 1994. PMID: 7528391 Review.

7

Clinical experience of the detection of prostate cancer in patients with benign prostate hyperplasia treated with finasteride. The Finasteride Study Group.

Stoner E, Round E, Ferguson D, Gormley GJ. Stoner E, et al. Among authors: gormley gj. J Urol. 1994 May;151(5):1296-300. doi: 10.1016/s0022-5347(17)35235-7. J Urol. 1994. PMID: 7512661 Clinical Trial.

8

Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia.

Pannek J, Marks LS, Pearson JD, Rittenhouse HG, Chan DW, Shery ED, Gormley GJ, Subong EN, Kelley CA, Stoner E, Partin AW. Pannek J, et al. Among authors: gormley gj. J Urol. 1998 Feb;159(2):449-53. doi: 10.1016/s0022-5347(01)63946-6. J Urol. 1998. PMID: 9649261 Clinical Trial.

9

Long-term effects of finasteride on prostate tissue composition.

Marks LS, Partin AW, Dorey FJ, Gormley GJ, Epstein JI, Garris JB, Macairan ML, Shery ED, Santos PB, Stoner E, deKernion JB. Marks LS, et al. Among authors: gormley gj. Urology. 1999 Mar;53(3):574-80. Urology. 1999. PMID: 10096387 Clinical Trial.

10

Effect of finasteride on prostate-specific antigen density.

Gormley GJ, Ng J, Cook T, Stoner E, Guess H, Walsh P. Gormley GJ, et al. Urology. 1994 Jan;43(1):53-8; discussion 58-9. doi: 10.1016/s0090-4295(94)80262-9. Urology. 1994. PMID: 7506854 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

142 results

Search Page